KalVista Pharmaceuticals (KALV) Free Cash Flow (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -34.25% |
| Oct 31, 2024 | 1.43% |
| Jul 31, 2024 | -171.22% |
| Apr 30, 2024 | 46.68% |
| Jan 31, 2024 | -40.50% |
| Oct 31, 2023 | 25.84% |
| Jul 31, 2023 | -17.75% |
| Apr 30, 2023 | -144.03% |
| Jan 31, 2023 | 55.24% |
| Oct 31, 2022 | 12.15% |
| Jul 31, 2022 | 11.96% |
| Apr 30, 2022 | -88.37% |
| Jan 31, 2022 | 28.31% |
| Oct 31, 2021 | -10.43% |
| Jul 31, 2021 | -62.68% |
| Apr 30, 2021 | -45.76% |
| Jan 31, 2021 | 4.58% |
| Oct 31, 2020 | -120.64% |
| Jul 31, 2020 | 71.41% |
| Apr 30, 2020 | 3.68% |
| Jan 31, 2020 | -65.35% |
| Oct 31, 2019 | 30.29% |
| Jul 31, 2019 | -5.44% |
| Apr 30, 2019 | 0.83% |
| Jan 31, 2019 | -20.75% |
| Oct 31, 2018 | -32.91% |
| Jul 31, 2018 | 3.72% |
| Apr 30, 2018 | -125.11% |
| Jan 31, 2018 | 483.56% |
| Oct 31, 2017 | -60.38% |
| Jul 31, 2017 | -72.13% |
| Apr 30, 2017 | 76.46% |
| Jan 31, 2017 | -167.53% |
| Oct 31, 2016 | 26.21% |
| Mar 31, 2016 | 3.27% |
| Dec 31, 2015 | -2.23% |
| Sep 30, 2015 | 18.30% |
| Jun 30, 2015 | -54.17% |
| Sep 30, 2014 | -60.51% |
| Jun 30, 2014 | -14.70% |